JB Chemicals & Pharmaceuticals Ltd - Stock Valuation and Financial Performance

BSE: 506943 | NSE: JBCHEPHARM | Pharmaceuticals & Drugs | Small Cap

JB Chemicals & Pharmaceuticals Ltd Share Price

1,643.80 -16.35 -0.98%
as on 23-Feb'24 16:59

DeciZen - make an informed investing decision on JB Chem & Pharma

Overall Rating
Bole Toh

1. Quality

2. Valuation

Overvalued

3. Price Trend

Semi Strong

JB Chemicals & Pharmaceuticals stock performance -

mw4me loader
P/E Ratio (SA):
50.89
Market Cap:
25,757.5 Cr.
52-wk low:
914.7
52-wk high:
1,935

Is JB Chemicals & Pharmaceuticals Ltd an attractive stock to invest in?

1. Is JB Chemicals & Pharmaceuticals Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that JB Chemicals & Pharmaceuticals Ltd is a good quality company.

2. Is JB Chemicals & Pharmaceuticals Ltd undervalued or overvalued?

The key valuation ratios of JB Chemicals & Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is JB Chemicals & Pharmaceuticals Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of JB Chemicals & Pharmaceuticals Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of JB Chem & Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
JB Chemicals & Pharmaceuticals Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
ROCE % 9.6%10.2%12.4%10.6%7.5%11.7%17.4%24.5%17.1%16.4%-
Value Creation
Index
-0.3-0.3-0.1-0.2-0.5-0.20.30.80.30.2-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 9571,0611,1651,1991,2551,5011,6411,8922,1902,8843,189
Sales YoY Gr.-11%9.8%2.9%4.7%19.6%9.3%15.3%15.7%31.7%-
Adj EPS 66.58.88.76.410.716.725.921.725.532.6
YoY Gr.-8.9%35.2%-1.6%-26.4%68.5%55.6%55.3%-16.4%17.4%-
BVPS (₹) 61.859.972.181.88792.593.5116.9132.1150181.2
Adj Net
Profit
101110149147106172258401335394506
Cash Flow from Ops. -11.7143171178116193272335147629-
Debt/CF from Ops. -80.710.30.30.10.10.10.20.8-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 13.1%18.1%20.7%31.7%
Adj EPS 17.5%31.9%15.1%17.4%
BVPS10.4%11.5%17.1%13.6%
Share Price 38% 58.5% 44.2% 68.8%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
Return on
Equity %
9.910.713.311.37.511.717.624.617.117.319.7
Op. Profit
Mgn %
16.218.619.61915.919.522.629.223.223.426.5
Net Profit
Mgn %
10.610.412.812.38.511.515.721.215.313.715.9
Debt to
Equity
0.10.10.10000000.2-
Working Cap
Days
16116221427629026922419122020388
Cash Conv.
Cycle
97100959698878175847356

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 20.69%

Net Profit is growing at healthy rate in last 3 years 15.10%

Sales growth is good in last 4 quarters at 15.42%

Return on Equity has declined versus last 3 years average to 19.70%

Latest Financials - JB Chemicals & Pharmaceuticals Ltd.

Standalone Consolidated
TTM EPS (₹) 32.6 33.1
TTM Sales (₹ Cr.) 3,189 3,385
BVPS (₹.) 181.2 183.7
Reserves (₹ Cr.) 2,796 2,835
P/BV 9.16 9.04
PE 50.89 50.10
From the Market
52 Week Low / High (₹) 914.65 / 1935.00
All Time Low / High (₹) 2.70 / 1935.00
Market Cap (₹ Cr.) 25,757
Equity (₹ Cr.) 15.5
Face Value (₹) 1
Industry PE 48.5

Management X-Ray of JB Chem & Pharma:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of JB Chem & Pharma

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Balance Sheet

(All Figures are in Crores.)

Profit And Loss

(All Figures in Cr. Adjusted EPS in Rs.)

Cash Flow

(All Figures are in Crores.)

JB Chemicals & Pharmaceuticals Ltd Stock News

JB Chemicals & Pharmaceuticals Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of JB Chem & Pharma on 23-Feb-2024 16:59 is ₹1,643.8.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 23-Feb-2024 16:59 the market cap of JB Chem & Pharma stood at ₹25,757.5.
The latest P/E ratio of JB Chem & Pharma as of 23-Feb-2024 16:59 is 50.89.
The latest P/B ratio of JB Chem & Pharma as of 23-Feb-2024 16:59 is 9.16.
The 52-week high of JB Chem & Pharma is ₹1,935 and the 52-week low is ₹914.6.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of JB Chem & Pharma is ₹3,189 ( Cr.) .

About JB Chemicals & Pharmaceuticals Ltd

Established in 1976, J.B.Chemicals & Pharmaceuticals Ltd. (JBCPL) is one of India’s fastest growing pharmaceutical companies. An integrated, research-oriented, public listed organisation with a focus on supplying affordable, quality products both in India and International markets, JBCPL is trusted by healthcare professionals globally.

JBCPL is widely committed to manufacturing a range of innovative specialty products that include various pharmaceutical dosage forms like tablets, injectable (vials, ampoules, form fill seal), creams & ointments, lozenges, herbal liquids and capsules. In India and International markets, JBCPL is also known as Unique Pharmaceutical Laboratories and is a division of JBCPL.

JBCPL exports too many countries worldwide with presence in US, Europe, Australia, South Africa, other developing countries, Russia and CIS. The Company continues to invest in growing its share in the regulated markets such as USA, Europe and Australia. JBCPL has a strong R&D and regulatory set-up for development of new drug delivery system and formulations, filing of ANDAs and DMFs. Its state-of-the-art manufacturing facilities are approved by health authorities of key regulated markets.

Business area of the company

J. B. Chemicals & Pharmaceuticals is engaged in the business of manufacturing and marketing of diverse range of pharmaceutical formulations, herbal remedies and APIs.

Milestones & awards

1996-97

  • Shri. Dinesh Mody, Director, JBCPL, receiving the Prestigious National Export Award/Trophy for the year 1996-97, from the Hon’ble Prime Minister of India, Shri. Atal Behari Vajpayee

1999

  • J. B. Chemical & Pharmaceuticals Ltd. is honoured with the IDMA Quality Excellence Award: ‘Certificate of Merit’ for distinction in quality manufacturing at its manufacturing unit in Panoli.

2000

  • Company awarded a Golden Status certificate by the Govt. of India.

2001

  • J.B. Chemical & Pharmaceuticals Ltd. receives CHEMEXCIL’s ‘First Award’ for Outstanding Export Performance of Pharmaceuticals in the large-scale manufacturer’s category. Received South Africa MCA approval for its tablets facility at Panoli.

2003

  • First ANDA filing with USFDA for Ciprofloxacin.
  • First company to market Rantac CD.
  • Approval from Columbian Drug Regulatory Authority INVIMA for its state-of-the-art facility at Panoli.

2004

  • Features in the Forbes Global list 100 for “Best under $1 Billion” in Asia-Pacific.
  • Receives its maiden USFDA approval to market Ciprofloxacin tablets in the US market.
  • UKMHRA approves JBCPL’s tablet manufacturing facility at Panoli.

2005

  • TGA Australia approves JBCPL’s tablet manufacturing facilities at Panoli, Gujarat, India.
  • JBCPL receives USFDA approval to market Fluconazole tablets in the US market.
  • JBCPL features in Forbes Asia Pacific 200 List for “Best under a Billion” for second year in a row.

2006

  • The ‘Niryat Shree’ Certificate of Excellence was awarded to Unique Pharmaceutical Laboratories Limited, a division of JBCPL, by the Federation of Indian Export Organisations (FIEO) for outstanding export performance in the category of Chemicals, Drugs, Pharma & Allied Products, Non-SSI for the year 2004-05.

2007

  • JBCPL’s Annual Report for the year ended March 31, 2005 was awarded a merit certificate by the South Asian Federation of Accountants (SAFA), an apex body of SAARC, for the Best Presented Accounts for the year 2005 in the category of “Hospitality, Health, Transport, Shipping, etc.’

2008

  • Made a strategic investment in a company in South Africa called Biotech Laboratories.

2011

  • Divested the OTC portfolio in Russia, Ukraine and CIS to J&J.

2016

  •  Resignation of a director - Dr. Niranjan Maniar due to health problem.

2017

  • Shri J. B. Mody, Chairman, receives Lifetime Achievement Award.
  • Mr. J. B. Mody’s Lifetime Achievement Award AV on 13-11-2017.

2018

  • US FDA has approved Company's Abbreviated New Drug Application (ANDA) for Midodrine Hydrochloride Tablets USP 2.5 mg, 5 mg. and 10 mg. (for treatment of orthostatic hypotension).

2020

  • This is to inform you that US FDA has approved Company's Abbreviated New Drug Application (ANDA) for Carbamazepine Extended Release Tablets USP 100 mg, 200 mg and 400 mg.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.